Table 2.

Relation of HIF-1α, VEGF-A and VEGF-C to clinicopathologic parameters

		Nuclear grade1		P value	Tumor size (cm)1		p value	Ki67 (%)1,2		P value	Pathologic stage1		P value
		1,2	3,4		< 7	≥ 7		low	high		1	2,3,4,
HIF-1α	nHIF-1α	49.5	39	0.006	48.6	43.6	0.057	43.9	48.1	0.134	48.1	44.5	0.165
(%)		(16.3–82.3)	(19.2–72.6)		(27.9–73.9)	(16.3–82.3)		(16.3–72.4)	(21.2–82.3)		(27.9–73.9)	(16.3–82.3)
	cHIF-1α	11.4	18.7	0.006	11.3	17.5	0.009	14.6	11.6	0.246	11.4	16.6	0.023
		(1.4–75)	(5.2–59.5)		(1.4–59.5)	(2.9–75)		(4.3–75)	(1.4–46.5)		(1.4–42.6)	(2.9–75)
VEGF-A	pVEGF-A	15	12.5	0.307	15	7.5	0.173	12.5	12.7	0.658	12.1	17.5	0.682
(%)		(0.00–94)	(0–75)		(0–94)	(0–75)		(0–94)	(0–75)		(0–94)	(0–75)
	dVEGF-A	6.7	30	<0.001	6.7	16.7	0.015	10.6	10	0.652	6.3	11.7	0.027
		(0–92.5)	(0–90)		(0–67.5)	(0–92.5)		(0–92.5)	(0–83.3)		(0–76.7)	(0–92.5)
VEGF-C	pVEGF-C	65	14	<0.001	64.2	27.9	0.007	45	55	0.913	61.3	33.3	0.042
(%)		(0–100)	(0–92.5)		(0–100)	(0–100)		(0–100)	(0–100)		(0–100)	(0–100)
	dVEGF-C	18.5	37	0.004	18	37.1	0.007	25	26.3	0.516	20	30	0.109
		(0–100)	(0–100)		(0–100)	(0–100)		(0–100)	(0–100)		(0–100)	(0–100)

¹Mann-Whitney U-test; median (range); ²cut-off is mean